LUT014 works by paradoxically reactivating MAPK, a key signaling pathway in the skin that anti-EGFR therapies shut down.

Researchers from the UCLA Health Jonsson Comprehensive Cancer Center and The University of Texas MD Anderson Cancer Center ...